<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-115133</identifier>
<setSpec>0034-9356</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Massive haemorrhage after bivalirudin anticoagulation in two heart transplant patients</dc:title>
<dc:description xml:lang="en">Heparin-induced thrombopenia is a common autoimmune complication. It is a prothrombotic state due to the formation of antibodies against heparin/platelet factor 4 complexes. In this situation drugs other than heparin must be used for anticoagulation during extracorporeal circulation (bypass) surgery. Two cases of heart transplantation are presented in whom bivalirudin was used as an anticoagulant during the cardiopulmonary bypass. Severe bleeding complications were observed in both patients. The diagnosis of heparin-induced thrombopenia needs to be improved, as well as the development of protocols for using new drugs other than heparin. For this reason, we have reviewed current protocols and alternative therapies to heparin(AU)</dc:description>
<dc:creator>Mirabet, S</dc:creator>
<dc:creator>Muñoz-Guijosa, C</dc:creator>
<dc:creator>Paniagua, P</dc:creator>
<dc:creator>Tauron, M</dc:creator>
<dc:creator>Padró, J. M</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La trombopenia inducida por heparina es una complicación autoinmunitaria frecuente. Se trata de un estado protrombótico debido a la formación de anticuerpos contra los complejos heparina/factor plaquetario 4. Ante esta situación es necesario el empleo de fármacos alternativos a la heparina para la anticoagulación durante la circulación extracorpórea. Se exponen 2 casos de trasplante cardiaco en los que se empleó bivalirudina como anticoagulante durante la circulación extracorpórea. En ambos pacientes se observó la aparición de complicaciones hemorrágicas severas. Es necesario mejorar el diagnóstico de la trombopenia inducida por heparina y desarrollar protocolos de empleo de nuevos fármacos alternativos a la heparina. Por ello revisamos los protocolos de actuación y las alternativas terapéuticas a la heparina(AU)</dc:description>
<dc:source>Rev Esp Anestesiol Reanim;60(7): 407-410, ago.-sept. 2013.</dc:source>
<dc:identifier>ibc-115133</dc:identifier>
<dc:title xml:lang="es">Hemorragia masiva después de anticoagulación con bivalirudina en 2 casos de pacientes con trasplante cardiaco</dc:title>
<dc:subject>^d932^s22020</dc:subject>
<dc:subject>^d24339^s22045</dc:subject>
<dc:subject>^d6622^s22012</dc:subject>
<dc:subject>^d932^s22073</dc:subject>
<dc:subject>^d6622^s22057</dc:subject>
<dc:subject>^d14306^s22012</dc:subject>
<dc:subject>^d14306^s22067</dc:subject>
<dc:subject>^d14306^s22036</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d29419^s22045</dc:subject>
<dc:subject>^d24339^s22083</dc:subject>
<dc:subject>^d5211^s22074</dc:subject>
<dc:subject>^d5211^s22048</dc:subject>
<dc:subject>^d5211^s22045</dc:subject>
<dc:type>article</dc:type>
<dc:date>201309</dc:date>
</metadata>
</record>
</ibecs-document>
